Skin Care Clinical Trial
Official title:
A Clinical Study to Assess the Local Cutaneous and Ocular Tolerance of a Developmental Cosmetic Facial Serum Formulation in Healthy Females With Sensitive Skin
Verified date | November 2020 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To determine the local cutaneous and ocular tolerance of a developmental cosmetic facial serum in healthy females with sensitive facial skin under normal conditions of use.
Status | Completed |
Enrollment | 90 |
Est. completion date | November 13, 2018 |
Est. primary completion date | November 13, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Subject provision of a signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study before any assessment is performed. - A subject who is willing and able to comply with scheduled visits, the application schedule, the lifestyle guidelines, and other study procedures. - A subject in good general and mental health with, in the opinion of the investigator or medically qualified designee (if the investigator is not suitably qualified), no clinically significant/relevant abnormalities in medical history or upon dermatologist and ophthalmologist examination, or condition, that would impact the subject's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements. - A subject with sensitive facial skin, defined as a positive response to a lactic acid sting test in the nasolabial area. - A subject with a dermatologist signs and symptoms of cutaneous irritation score of greater than or equal to 0.5 (very slight) for erythema. - A subject with a dermatologist signs and symptoms of cutaneous irritation score of greater than or equal to 0.5 (very slight) for dryness. - A subject with a dermatologist signs and symptoms of cutaneous irritation score of 0 (none) or 0.5 (very sight) for scaling. - A subject with a dermatologist signs and symptoms of cutaneous irritation score of 0 (none) or 0.5 (very sight) for edema. - A subject with an ophthalmologist total signs and symptoms of ocular irritation score of 0 (none). Exclusion Criteria: - A subject who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or, a GSK CH employee directly involved in the conduct of the study or a member of their immediate family. - A subject who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation. - A subject with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the subject inappropriate for entry into this study. - A subject who is pregnant (self-reported). - A subject who is breastfeeding. - A subject with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients. - A subject who, in the opinion of the investigator or medically qualified designee, should not participate in the study. - A subject unwilling or unable to comply with the Lifestyle Considerations required by this study, as described in this protocol. - A subject with current or recent (within last 6 months before the start of the study) history of atopic lesions and/or eczema. - A subject with a history of allergic reactions to topical-use products, cosmetics or medications or their ingredients. - A subject with any history of significant diseases or medical conditions known to alter skin or eye appearance or physiologic response (e.g. diabetes) which could, in the opinion of the Investigator, preclude topical application of the investigational products and/or interfere with the evaluation of the test site reaction. - A subject presenting open sores, pimples, or cysts at the application site (face). - A subject with an active dermatosis (local or disseminated) that might interfere with the results of the study. - A subject with a dermatologist signs and symptoms of cutaneous irritation score of 3 (severe) for erythema, edema, scaling or dryness. - A subject considered immune-compromised. - A subject currently using any medication which in the opinion of the investigator, may affect the evaluation of the investigational product, or place the subject at undue risk. - A subject who has used any of the following topical or systemic medications up to two weeks before the screening visit: immuno-suppressants, antihistamines, non-steroidal anti-inflammatory drugs (NSAIDS), and/or corticosteroids. - A subject who has used oral or topical treatment with vitamin A acid and/or its derivatives up to 1 month before the screening visit. - A subject who has been vaccinated up to 1 month before the screening visit or who are intending to receive a vaccination during their participation in the study. - A subject with a recent history (within the last 5 years) of alcohol or other substance abuse. - A subject with any skin marks on the face that might interfere with the evaluation of possible skin reactions (e.g. pigmentation disorders, vascular malformations, scars, tattoos, excessive hair, numerous freckles). - Subjects with corneal ulcers, keratoconus, blepharitis, meibomitis, pterygium, chemosis,moderately or severe hyperemia or other active ocular diseases. - A subject who has previously been enrolled in this study. |
Country | Name | City | State |
---|---|---|---|
Germany | GSK Investigational Site | Schenefeld | Schleswig-Holstein |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With a Unit Change of Greater Than (>) 1 in Signs and Symptoms of Cutaneous Irritation Total Scores From Baseline to 21 Days of Product Use | A qualified dermatologist visually assessed the signs and symptoms of cutaneous irritation for dermal erythema, dryness, scaling, and edema on a scale with a score range of 0 to 3, where 0=none, 0.5=very slight, 1=slight, 2=moderate, 3=severe. Cutaneous irritation total score = dermal score of erythema + dermal score of dryness + dermal score of scaling + dermal score of edema. Total possible score range is 0 to 12 (higher value indicated more cutaneous irritation). Change from baseline for 21 days of product use = total score at Day 21 minus total score at baseline. Participants with a unit change of greater than (>) 1 in total score (TS) of cutaneous irritation from baseline to 21 days of product use, are reported in this outcome measure. | Baseline and Day 21 | |
Secondary | Number of Participants With a Unit Change of >1 in Signs and Symptoms of Ocular Irritation Total Scores From Baseline to 21 Days of Product Use | A qualified ophthalmologist visually assessed the signs and symptoms of ocular irritation for ocular eczema of the eyelid, conjunctivitis, follicles and chemosis conjunctivae on a scale with a score range of 0 to 3, where 0=none, 0.5=very slight, 1=slight, 2=moderate, 3=severe. Ocular irritation total score = ocular score of eczema of the eyelid + ocular score of conjunctivitis + ocular score of follicles + ocular score of chemosis conjunctivae. Total possible score range is 0 to 12 (higher value indicated more ocular irritation). Change from baseline for 21 days of product use = total score at Day 21 minus total score at baseline. Participants with a unit change of > 1 in total score of ocular irritation from baseline to 21 days of product use, are reported in this outcome measure. | Baseline and Day 21 | |
Secondary | Number of Participants With a Unit Change of >1 in Signs and Symptoms of Cutaneous Irritation (Self-assessment) From Baseline to 1 to 2 Hours Post First Product Use and 21 Days of Product Use | Participants were instructed to self-assess any sensations of cutaneous discomfort for redness, dryness, stinging/burning, itching and tightness on a scale with a score range of 0 to 3, where 0=none, 0.5=very slight, 1=slight, 2=moderate, 3=severe. Participant self-assessment of cutaneous irritation total score = redness + dryness + itching + stinging/burning + tightness. Total possible score range is 0 to 15 (higher value indicated more cutaneous irritation). Change from baseline at 1-2 hours post first use = total score at 1 to 2 hours minus total score at baseline. Similarly, change from baseline for 21 days of product use = total score at Day 21 minus total score at baseline. Participants with a unit change of >1 in total score of cutaneous irritation from baseline to 1-2 hours post first product use and 21 days of product use, are reported in this outcome measure. | Baseline, 1-2 hours post first use, Day 21 | |
Secondary | Number of Participants With a Unit Change of >1 in Signs and Symptoms of Ocular Irritation (Self-assessment) From Baseline to 1 to 2 Hours Post First Product Use and 21 Days of Product Use | Participants were instructed to self-assess any sensations of ocular discomfort for redness, dryness, stinging/burning and itching on a scale with a score range of 0 to 3, where 0=none, 0.5=very slight, 1=slight, 2=moderate, 3=severe. Participant self-assessment of ocular irritation total score = redness + dryness + itching + stinging/burning. Total possible score range is 0 to 12 (higher value indicated more ocular irritation). Change from baseline at 1-2 hours post first use = total score at 1 to 2 hours minus total score at baseline. Similarly, change from baseline for 21 days of product use = total score at Day 21 minus total score at baseline. Participants with a change of > 1 in total score of ocular irritation from baseline to 1-2 hours post first product use and Day 21 days of product use, are reported in this outcome measure. | Baseline, 1-2 hours post first use, Day 21 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03302559 -
Study to Assess the Cosmetic Changes in the Facial Skin After Use of a Topical Retinoid Product in Participants With Moderate to Severe Photodamage
|
N/A | |
Completed |
NCT04510103 -
A Controlled Clinical Study of 2 Different Moisturizers for the Relief of Dry Skin
|
N/A | |
Active, not recruiting |
NCT04972747 -
The Effect of Skin Care Applied With Two Different Oils on Skin Integrity and Growth Parameters in Premature Babies
|
N/A | |
Completed |
NCT04557371 -
A Study to Assess the Local Cutaneous and Ocular Tolerance of Three Developmental Facial Skin-care Formulations.
|
N/A | |
Completed |
NCT03824886 -
Enhancing SKIN Health and Safety in Aged CARE
|
N/A | |
Completed |
NCT03402373 -
Evaluation of the Nutritional Supplement Lycoderm on Its Impact on Skin Parameters
|
N/A | |
Completed |
NCT03119688 -
To Assess the Mildness of a Cosmetic Cleanser in Healthy Participants Using the Forearm-Controlled Application Technique (FCAT)
|
N/A | |
Recruiting |
NCT05337670 -
Probiotics Regulates Skin Care in Children
|
N/A | |
Recruiting |
NCT05005611 -
Probiotics Regulates Skin Care in Children
|
N/A | |
Not yet recruiting |
NCT05888311 -
Evaluation of the Protection of a Liquid Bandage
|
N/A | |
Not yet recruiting |
NCT05876546 -
Evaluation of Skin Irritancy and Sensitization of a Liquid Bandage
|
N/A | |
Completed |
NCT03233009 -
To Investigate Primary Irritation Potential of Four Skin Serum Products on Human Subjects Assessed by 24 Hour Patch Test
|
N/A | |
Completed |
NCT02106403 -
A Study to Evaluate the Cooling Sensation and Consumer Liking of a Skin Disinfectant Spray
|
N/A | |
Active, not recruiting |
NCT03192592 -
Safety and Effectiveness Evaluation of the Apotech® Diabetic Body Moisturizer
|
N/A | |
Completed |
NCT03103906 -
Evaluation of the Cosmetic Benefit of a Skin Cream in Healthy Females With Mild to Advanced Photo-damaged Facial Skin Who Have Undergone a Glycolic Acid Facial Peel Procedure
|
N/A | |
Completed |
NCT03175562 -
To Assess the Cutaneous Irritation and Sensitization Potential of a Cosmetic Facial Product Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Participants
|
N/A | |
Completed |
NCT03183518 -
To Assess the Photosensitisation and Photoallergy Potential of a Cosmetic Facial Product in Healthy Participants
|
N/A | |
Completed |
NCT05266209 -
Comparison of Coconut and Sunflower Oil Application in Preserving Babies' Skin Integrity
|
N/A | |
Not yet recruiting |
NCT05738018 -
Evaluating Patient Experiences in Skin Care Clinical Studies
|
||
Completed |
NCT02603029 -
Influence of of Cream With the Silver Fir Wood Extract (Belinal) on Skin
|
N/A |